软骨肉瘤（CS）是一种罕见的恶性骨肉瘤，主要影响股骨和骨盆的软骨细胞。虽然大多数亚型表现出缓慢的生长，预后非常好，一些侵袭性亚型的总体生存率较差.CS以其对化疗和放疗的抗性而闻名，离开手术作为唯一有效的治疗选择。冷物理血浆（CPP）已在体外作为一种潜在的治疗方法进行了探索，证明对CS细胞有积极的抗肿瘤作用。这项研究调查了CPP与细胞抑制剂组合对CS细胞的协同作用。化疗药物顺铂，阿霉素,将长春新碱应用于两种CS细胞系(CAL-78和SW1353)。在确定其IC20和IC50后，将其与CPP在两种细胞系中组合以评估其对细胞增殖的影响，生存能力，新陈代谢，和凋亡。与单独的细胞抑制疗法相比，这种组合方法显着降低了细胞增殖和活力，同时增加了凋亡信号。CPP和化疗药物的组合在靶向化学抗性CS细胞方面显示出希望，有可能改善临床患者的预后。
Chondrosarcoma (CS) is a rare malignant bone sarcoma that primarily affects cartilage cells in the femur and pelvis. While most subtypes exhibit slow growth with a very good prognosis, some aggressive subtypes have a poorer overall survival. CS is known for its resistance to chemotherapy and radiotherapy, leaving surgery as the sole effective therapeutic option. Cold physical plasma (CPP) has been explored in vitro as a potential therapy, demonstrating positive anti-tumor effects on CS cells. This study investigated the synergistic effects of combining CPP with cytostatics on CS cells. The chemotherapeutic agents cisplatin, doxorubicin, and vincristine were applied to two CS cell lines (CAL-78 and SW1353). After determining their IC20 and IC50, they were combined with CPP in both cell lines to assess their impact on the cell proliferation, viability, metabolism, and apoptosis. This combined approach significantly reduced the cell proliferation and viability while increasing the apoptosis signals compared to cytostatic therapy alone. The combination of CPP and chemotherapeutic drugs shows promise in targeting chemoresistant CS cells, potentially improving the prognosis for patients in clinical settings.
PDF(Pubmed)